• Explore /
  • Poster
  • / Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.

Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure.

Abstract Poster

Authors

null

Stefanie L. Groenland

The Netherlands Cancer Institute–Antoni van Leeuwenhoek, Amsterdam, Netherlands

Stefanie L. Groenland , Ruben A.G. van Eerden , Stijn L.W. Koolen , Dirk Jan A.R. Moes , Alex Imholz , Sofie Wilgenhof , Winette T.A. Van Der Graaf , Hans Gelderblom , Jos H. Beijnen , Ron H.J. Mathijssen , Alwin Huitema , Neeltje Steeghs

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Pharmacology/Pharmacodynamics/Pharmacogenetics

Clinical Trial Registration Number

NL6695

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3598)

DOI

10.1200/JCO.2020.38.15_suppl.3598

Abstract #

3598

Poster Bd #

328

Abstract Disclosures

Similar Posters

First Author: Vanessa Anne Eulo

First Author: Giacomo Nuvola

Poster

2023 ASCO Genitourinary Cancers Symposium

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

First Author: Jianbo Wang

First Author: Christina Parrinello